{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:15:39Z","timestamp":1778051739961,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"H.W.&J. Hector Stiftung, M2206"},{"name":"H.W.&J. Hector Stiftung, M2206 Stiftung Gerdes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41375-026-02944-z","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:53:05Z","timestamp":1774857185000},"page":"1076-1079","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1930-1668","authenticated-orcid":false,"given":"Hanna","family":"Kirchhoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Schoenherr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-2725","authenticated-orcid":false,"given":"Anke K.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3362-5814","authenticated-orcid":false,"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2944_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2018-08-832105","volume":"133","author":"F Ravandi","year":"2019","unstructured":"Ravandi F. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2019;133:130\u20136.","journal-title":"Blood"},{"key":"2944_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N Gokbuget","year":"2024","unstructured":"Gokbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1903\u201330.","journal-title":"Blood"},{"key":"2944_CR3","doi-asserted-by":"crossref","unstructured":"Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621\u201332.","DOI":"10.1038\/nrm2952"},{"key":"2944_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/s41375-018-0315-6","volume":"33","author":"M Scherr","year":"2019","unstructured":"Scherr M, Kirchhoff H, Battmer K, Wohlan K, Lee CW, Ricke-Hoch M, et al. Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia. 2019;33:1313\u201323.","journal-title":"Leukemia"},{"key":"2944_CR5","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood.2020008544","volume":"137","author":"H Kirchhoff","year":"2021","unstructured":"Kirchhoff H, Karsli U, Schoenherr C, Battmer K, Erschow S, Talbot SR, et al. Venetoclax and dexamethasone synergize with inotuzumab-ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021;137:2657\u201361.","journal-title":"Blood"},{"key":"2944_CR6","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s41418-025-01487-7","volume":"32","author":"JN Gong","year":"2025","unstructured":"Gong JN, Djajawi TM, Moujalled DM, Pomilio G, Khong T, Zhang LP, et al. Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents, selectively targeting pro-survival BCL2 proteins. Cell Death Differ. 2025;32:1382\u201396.","journal-title":"Cell Death Differ"},{"key":"2944_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1124\/mol.109.060780","volume":"77","author":"LM High","year":"2010","unstructured":"High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O\u2019Brien R, Khaw SL, et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia, resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010;77:483\u201394.","journal-title":"Mol Pharmacol"},{"key":"2944_CR8","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","volume":"75","author":"SE Alford","year":"2015","unstructured":"Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, et al. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75:1366\u201375.","journal-title":"Cancer Res"},{"key":"2944_CR9","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","volume":"24","author":"R Kuribara","year":"2004","unstructured":"Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K, et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol. 2004;24:6172\u201383.","journal-title":"Mol Cell Biol"},{"key":"2944_CR10","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118:1663\u201374.","journal-title":"Blood"},{"key":"2944_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488\u201396.","journal-title":"J Clin Oncol"},{"key":"2944_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149\u201359.","journal-title":"Lancet Oncol"},{"key":"2944_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado7120","volume":"10","author":"A Judd","year":"2024","unstructured":"Judd A, Bawa B, Buck W, Tao Z, Li Y, Mitten M, et al. BCL-XL\u2013targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors. Sci Adv. 2024;10:eado7120.","journal-title":"Sci Adv"},{"key":"2944_CR14","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11:1440\u201353.","journal-title":"Cancer Discov"},{"key":"2944_CR15","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347.","journal-title":"Nat Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02944-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02944-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02944-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:26:20Z","timestamp":1778048780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02944-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2944"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02944-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}